Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Home

Get in touch

Menu

For your Patients

Prescribing Information

Discover the post-prescription materials available to support your patients through their TZIELD journey. These comprehensive materials provide key information for both children (ages 8 and over), adults and caregivers about how TZIELD works, what to expect from their treatment, key safety information and their next steps.

On this page

— Patient Guides - Key Safety Information
— Paediatric Patient Pack
— Adult Patient Pack
 

Patient Website

The patient website is the go-to digital platform for your patients to explore information about their treatment, what to expect and find additional resources and links. This can be accessed on desktop or on the go, on mobile.

Please note: All of the below resources will be available through the patient website. Any physical copies can only be distributed by you to your patients.

Link to patient website

Patient Guides - Key Safety Information

Risk Minimisation Material - Guide for Patients

Your patients should read this material alongside the Patient Information Leaflet (PIL) before their treatment, as it contains key safety information.

Download Guide for Patients

Patient Information Leaflet

This Patient Information Leaflet contains key safety information about your patient's treatment with Tzield.  You can share this material together with the Guide for Patients.

Download PIL

 

Paediatric Patient Pack

Order the Paediatric Patient Pack for your patients and their caregivers. This pack is designed with age appropriate content for ages 8-13 to help them understand their treatment, what to expect and their ongoing care. This Patient Pack is made up of three items:

  • Wallet: A folder to store guides in one place including a treatment tracker, allowing patients to track how many infusions are complete.
  • Handbook: Contains practical information about what to expect before, during and after their treatment.
  • Guide for Patients: The Risk Minimisation Material that should be read alongside the PIL to inform patients about TZIELD key safety information.

Download the digital version here

Please use the order form below to order packs for your patients or contact your Sanofi representative.

 

Adult Patient Pack

Order the Adult Patient Pack for your patients and their caregivers. This pack aims to help patients understand their treatment, what to expect and their ongoing care. This Patient Pack is made up of three items:

  • Wallet: A folder to store guides in one place including a treatment tracker, allowing patients to track how many infusions are complete.
  • Handbook: Contains practical information about what to expect before, during and after their treatment.
  • Guide for Patients: The Risk Minimisation Material that should be read alongside the PIL to inform patients about TZIELD key safety information.

Download the digital version here

Please use the order form below to order packs for your patients or contact your Sanofi representative.

Want printed copies of these materials?

Order from your Sanofi representative or by filling out this form.

Get in Touch with Us

Questions? Leave your details and we'll reach out to you at your preferred time.

Get in touch

INDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.1

PIL, patient information leaflet.
 

  1. TZIELD® (teplizumab) UK Summary of Product Characteristics.

MAT-XU-2600466 (v2.0) | June 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com
Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025